Unfolding dermatologic spectrum of Behçet’s disease in Italy: real-life data from the International AIDA Network Behçet’s disease Registry
-
Published:2023-10-06
Issue:8
Volume:18
Page:2245-2252
-
ISSN:1828-0447
-
Container-title:Internal and Emergency Medicine
-
language:en
-
Short-container-title:Intern Emerg Med
Author:
D’Onghia Martina, Cinotti Elisa, Cartocci Alessandra, Vitale Antonio, Caggiano Valeria, Tognetti Linda, La Marca Francesca, Sota Jurgen, Gentileschi Stefano, Rubegni Giovanni, Lopalco Giuseppe, Guerriero Silvana, Govoni Marcello, Monti Sara, Ruscitti Piero, Angeli Fabrizio, Carubbi Francesco, Giacomelli Roberto, Ciccia Francesco, Piga Matteo, Emmi Giacomo, Costi Stefania, Sebastiani Gian Domenico, Iannone Florenzo, Spedicato Veronica, Alessio Giovanni, Ruffilli Francesca, Milanesi Alessandra, Gentile Martina, Crisafulli Francesca, Alunno Alessia, Navarini Luca, Iacono Daniela, Cauli Alberto, Ricci Francesca, Gaggiano Carla, Tarsia Maria, Bartoloni Elena, Conti Giovanni, Viapiana Ombretta, Gobbi Francesca Li, de Paulis Amato, Parronchi Paola, Del Giudice Emanuela, Barone Patrizia, Olivieri Alma Nunzia, Bizzi Emanuele, Maggio Maria Cristina, Balistreri Alberto, Frediani Bruno, Tosi Gian Marco, Fabiani Claudia, Rubegni Pietro, Cantarini LucaORCID
Abstract
AbstractBehçet’s disease (BD) is a heterogeneous multifactorial autoinflammatory disease characterized by a plethora of clinical manifestations. Cutaneous lesions are considered hallmarks of the disease. However, their evolution over time and a thorough description are scarcely reported in non-endemic regions. The aim of this study was to detail BD skin manifestations and their evolution over time in Italy, as well as the dermatological prognostic impact of specific cutaneous features in long-standing disease. Data were collected in a double fashion, both retrospectively and prospectively, from the AutoInflammatory Disease Alliance (AIDA) international registry dedicated to BD, between January 2022 and December 2022. A total of 458 Italian patients were included. When assessing skin manifestations course, the constant or sporadic presence or absence of cutaneous involvement between onset and follow-up was considered. Oral ulcers (OU) (88.4%) and genital ulcers (GU) (52.6%), followed by skin involvement (53.7%) represented the most common presenting mucocutaneous manifestations at disease onset. Up to the time of enrolment into the AIDA registry, 411 (93.8%) patients had suffered from OU and 252 (57.9%) from GU; pseudofolliculitis (PF) accounted for the most common skin manifestation (170 patients, 37.1%), followed by erythema nodosum (EN) (102 patients, 22.3%), skin ulcers (9 patients, 2%) and pyoderma gangrenosum (4 patients, 0.9%). A prospective follow-up visit was reported in 261/458 patients; 24/148 (16.2%) subjects with skin involvement as early as BD onset maintained cutaneous lesions for the entire period of observation, while 120 (44.1%) patients suffered from sporadic skin involvement. Conversely, 94/113 (83.2%) with no skin involvement at disease onset did not develop skin lesions thereafter. At follow-up visits, cutaneous involvement was observed in 52 (20%) patients, with a statistically significant association between PF and constant skin involvement (p = 0.031). BD in Italy is characterized by a wide spectrum of clinical presentations and skin manifestations in line with what is described in endemic countries. Patients with skin disease at the onset are likely to present persistent cutaneous involvement thereafter; mucocutaneous lesions observed at the onset, especially PF, could represent a warning sign for future persistent skin involvement requiring closer dermatological care.
Funder
Università degli Studi di Siena
Publisher
Springer Science and Business Media LLC
Subject
Emergency Medicine,Internal Medicine
Reference24 articles.
1. Yazici Y, Hatemi G, Bodaghi B, Cheon JH, Suzuki N, Ambrose N, Yazici H (2021) Behçet syndrome. Nat Rev Dis Primers 7(1):67. https://doi.org/10.1038/s41572-021-00301-1 2. Alibaz-Oner F, Direskeneli H (2022) Update on the diagnosis of Behcet’s disease. Diagnostics (Basel) 13(1):41. https://doi.org/10.3390/diagnostics13010041 3. Davatch F, Shahram F, Chams-Davatchi C, Shams H, Nadji A, Akhlaghi M, Faezi T, Ghodsi Z, Faridar A, Ashofteh F (2010) Behcet’s disease: from East to West. Clin Rheumatol 29(8):823–833. https://doi.org/10.1007/s10067-010-1430-6 4. Azizlerli G, Köse AA, Sarica R, Gül A, Tutkun IT, Kulaç M, Tunç R, Urgancioğlu M, Dişçi R (2003) Prevalence of Behcet’s disease in Istanbul. Turkey Int J Dermatol 42(10):803–806. https://doi.org/10.1046/j.1365-4362.2003.01893.x 5. Hammam N, Li J, Evans M, Kay JL, Izadi Z, Anastasiou C, Gianfrancesco MA, Yazdany J, Schmajuk G (2021) Epidemiology and treatment of Behcet’s disease in the USA: insights from the rheumatology informatics system for effectiveness (RISE) registry with a comparison with other published cohorts from endemic regions. Arthritis Res Ther 23(1):224. https://doi.org/10.1186/s13075-021-02615-7
|
|